Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy

Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy

Objective  To investigate the effect of 99mTc-labeled RGD peptide (99mTc-RGD) on regulating the tumor immune microenvironment and enhancing the anti-tumor effect of immunotherapy when combined with anti-programmed death-ligand 1 (PD-L1) antibody.  Methods  The expression of PD-L1 on tumor cells was...

Full description

Bibliographic Details
Main Authors: WEN Xuejun, ZHOU Wuhao, GUO Zhide, ZHANG Xianzhong
Format: Article
Language:zho
Published: Editorial Office of Medical Journal of Peking Union Medical College Hospital 2023-07-01
Series:Xiehe Yixue Zazhi
Subjects:
radiopharmaceuticals
pd-l1
tumor immunotherapy
tumor models
Online Access:https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2023-0155

Internet

https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2023-0155

Similar Items